# Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

> **NCT00902538** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 2204 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Olmesartan medoxomil 40 mg - Amlodipine 10 mg
- **DRUG:** Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg
- **DRUG:** Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
- **DRUG:** OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
- **DRUG:** OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
- **DRUG:** OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg

## Key facts

- **NCT ID:** NCT00902538
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-09
- **Final completion:** 2010-10
- **Target enrollment:** 2204 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902538, "Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT00902538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*